“Global Life Sciences Quality Management Software Market to reach a market value of 7.17 Billion by 2031 growing at a CAGR of 12.6%”
The Global Life Sciences Quality Management Software Market size is expected to reach $7.17 billion by 2031, rising at a market growth of 12.6% CAGR during the forecast period.
The North America region witnessed 38% revenue share in the market in 2023. This significant share is attributed to North America's well-established life sciences industry, which includes numerous pharmaceutical and biotech firms that require advanced quality management solutions to comply with stringent regulatory standards set by agencies such as the FDA. The presence of major market players and continuous technological advancements further bolster the adoption of quality management software in this region.
The life sciences industry has embraced cloud-based technologies as they provide a flexible and scalable approach to managing quality management systems (QMS). Cloud solutions enable life sciences organizations to securely store vast amounts of data and access them from anywhere, facilitating real-time collaboration and decision-making. This has led to a growing shift from traditional on-premise solutions to cloud-based platforms, as they reduce the need for heavy infrastructure investments and maintenance. Thus, cloud-based life sciences quality management software offers scalability, flexibility, and compliance advantages that are pivotal in meeting the industry’s evolving needs.
Additionally, Patient safety and product quality are at the core of the life sciences industry, especially as companies are tasked with meeting stringent regulatory standards and maintaining public trust. As the demand for new medications, medical devices, and treatments increases, ensuring these products meet the highest quality standards is critical. This software is key in monitoring and improving product quality, from development to post-market surveillance. Therefore, the growing focus on patient safety and product quality drives the need for sophisticated quality management systems that ensure compliance and efficacy across life sciences industries.
However, One of the main challenges life sciences organizations face when adopting quality management software is the significant upfront costs associated with software implementation. Implementing a new QMS often involves substantial expenditures on software licenses, hardware infrastructure, and training. Many life sciences companies, particularly small and mid-sized organizations, may struggle with the financial burden of these initial investments, especially when they need to prioritize other operational costs. In conclusion, this software's high implementation and maintenance costs pose a significant challenge to organizations, particularly those with limited budgets.
Moreover, Many life sciences companies postponed or cancelled their Quality Management Software implementation projects due to budget constraints and shifting priorities during the pandemic. Budgets for new software purchases and upgrades were reduced as companies diverted funds to immediate pandemic-related needs and emergency measures. Disruptions in global supply chains affected the availability of hardware and support services required for deploying and maintaining QMS. Thus, the COVID-19 pandemic had a negative impact on the market.
The leading players in the market are competing with diverse innovative offerings to remain competitive in the market. The above illustration shows the percentage of revenue shared by some of the leading companies in the market. The leading players of the market are adopting various strategies in order to cater demand coming from the different industries. The key developmental strategies in the market are Acquisitions, and Partnerships & Collaborations.
By end use, this market is divided into pharmaceutical firms, biotech firms, and CROs/CDMOs. The biotech firms segment procured 31% revenue share in the market in 2023. Biotech firms, which are heavily involved in innovative research and development activities, utilize quality management software to streamline their operations and maintain compliance with regulatory requirements. These software solutions support biotech companies in managing quality throughout the product development lifecycle, from early-stage research to clinical trials and commercialization.
On the basis of deployment mode, this market is segmented into cloud & web-based and on-premises. In 2023, the on-premises segment attained 25% revenue share in the market. Concerns over data security, regulatory compliance, and the need for complete control over IT environments often drive this preference. Large organizations particularly favor on-premises solutions with established IT infrastructures and highly sensitive data requiring stringent security measures.
Based on application, the market is divided into data management, regulatory & compliance management, corrective action preventive action (CAPA) management, change management, audit management, risk management, non-conformances management, supplier management, training management, inspection management, and others. The regulatory & compliance management segment procured 15% revenue share in the market in 2023. This segment is crucial in helping life sciences companies adhere to stringent regulatory requirements and industry standards. The increasing complexity of regulations and the need for automated systems to manage compliance processes efficiently are significant drivers for this segment.
Free Valuable Insights: Global Life Sciences Quality Management Software Market size to reach USD 7.17 Billion by 2031
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific region generated 30% revenue share in the market in 2023. This notable share highlights the region’s rapid growth and increasing adoption of quality management solutions in the life sciences sector. Factors contributing to this growth include the expanding pharmaceutical and biotechnology industries, increasing clinical trials, and rising investments in healthcare infrastructure.
| Report Attribute | Details |
|---|---|
| Market size value in 2023 | USD 2.80 Billion |
| Market size forecast in 2031 | USD 7.17 Billion |
| Base Year | 2023 |
| Historical Period | 2020 to 2022 |
| Forecast Period | 2024 to 2031 |
| Revenue Growth Rate | CAGR of 12.6% from 2024 to 2031 |
| Number of Pages | 297 |
| Tables | 420 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Market Share Analysis, Porter’s 5 Forces Analysis, Company Profiling, Companies Strategic Developments, SWOT Analysis, Winning Imperatives |
| Segments covered | Application, Deployment Mode, End Use, Region |
| Country scope |
|
| Companies Included | AmpleLogic, Hexagon AB, Qualityze Inc., Veeva Systems, Inc., SimplerQMS, Dassault Systemes SE, MasterControl Solutions Inc., Ideagen Plc, IQVIA Holdings, Inc., and Honeywell International Inc. |
By Application
By Deployment Mode
By End Use
By Geography
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 